|
|
Article: Readying For Cephalon Merger, CIMA Launches Phase III Early.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
CIMA Labs Inc. might have became a somewhat more attractive takeover subject for Cephalon Inc. by starting enrollment in a Phase III study with its OraVescent Fentanyl a little ahead of schedule, although the company reported a dip in revenues for the first quarter and a significant dent in operating income at the same time it announced the trial's start.
CIMA's stock (NASDAQ:CIMA) fell 36 cents Friday to close at $31.34.
Revenue guidance for the first quarter had been "essentially on target," said James Hawley, chief financial officer for CIMA, during a conference call.
Regarding the Phase III study, originally ...